SCHEMBL6717232

SCHEMBL6717232

Cc1cccc(NC(=O)C(NC(=S)Nc2ccccc2[N+](=O)[O-])c2ccccc2)c1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.53
MEN1 O00255 5/20 0.53
KMT2A Q03164 5/20 0.53
LMNA P02545 4/20 0.53
MAPT P10636 6/20 0.52
NPSR1 Q6W5P4 2/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.49
CRHBP P24387 2/20 0.48
CRHR2 Q13324 2/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
POLB P06746 2/20 0.46
NPBWR1 P48145 1/20 0.44
MCHR1 Q99705 1/20 0.44
ALOX12 P18054 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6713812 0.93 ALDH1A1 (0.56) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL6716834 0.93 ALDH1A1 (0.56) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL6713795 0.91 ALDH1A1 (0.54) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL6723832 0.85 SMN1; SMN2 (0.54) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL6717195 0.85 MAPT (0.54) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL6723449 0.84 SMN1; SMN2 (0.50) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL6716952 0.84 SMN1; SMN2 (0.53) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL6717494 0.84 SMN1; SMN2 (0.50) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL8347237 0.84 MAPT (0.49) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL8346790 0.84 KMT2A (0.47) ALDH1A1MEN1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 ALDH1A1 572/4885MEN1 2933/4885KMT2A 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.